The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of Keytruda (pembrolizumab), an anti-PD-1 therapy, in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumors express PD-L1 (Combined Positive Score ≥10) and who have not received prior chemotherapy for metastatic disease.
Sidney Kimmel Cancer Center at Jefferson Health can add the word “Comprehensive” to its name, becoming the 57 institution to earn this top-level designation from NCI. xxx:more
